Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080135 | 1.00 | CTSK (0.40) | CTSKCA1CA2CA7SMN1; SMN2 | |
| SCHEMBL211053 | 0.86 | CTSK (0.45) | CTSKCA1CA2CA7SMN1; SMN2 | |
| SCHEMBL12290180 | 0.86 | CTSK (0.45) | CTSKCA1CA2CA7SMN1; SMN2 | |
| SCHEMBL211054 | 0.86 | CTSK (0.45) | CTSKCA1CA2CA7SMN1; SMN2 | |
| SCHEMBL6483144 | 0.82 | CTSK (0.42) | CTSKCA1CA2CA7ATM | |
| SCHEMBL6483146 | 0.82 | CTSK (0.42) | CTSKCA1CA2CA7ATM | |
| SCHEMBL6169481 | 0.82 | CTSK (0.42) | CTSKCA1CA2CA7ATM | |
| SCHEMBL7743860 | 0.81 | CTSK (0.49) | CTSKCA1CA2CA7SMN1; SMN2 | |
| SCHEMBL5025247 | 0.81 | SYK (0.43) | CTSKCA1CA2CA7ATM | |
| SCHEMBL29846381 | 0.78 | AAK1 (0.48) | CTSKCA1CA2CA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| WO-2008156817-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | CTSK 152/4885CA1 189/4885CA2 301/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | CTSK 94/4885CA1 624/4885CA2 338/4885 |
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CTSK 71/4885CA1 1110/4885CA2 844/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | CTSK 61/4885CA1 1184/4885CA2 508/4885 |
| US-20090312369-A1 | Renin Inhibitors | ACE, REN, DNPEP | CTSK 104/4885CA1 333/4885CA2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.